MF
MDGL icon

Magnetar Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Magnetar Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,811
Closed -$1.99M – 1350
2026
Q1 		$1.99M Buy
+3,811
New +$1.82M 0.02% 317
2025
Q3 		– Sell
-6,730
Closed -$2.04M – 1060
2025
Q2 		$2.04M Buy
+6,730
New +$2.01M 0.01% 345

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Magnetar Financial's MDGL Position: Q2 2026 in Review

Magnetar Financial sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 3,811 shares — an estimated $1.99M sold.

Magnetar Financial first reported a position in MDGL in Q2 2025 and held it in 2 quarters. The position peaked at $2.04M in Q2 2025. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Magnetar Financial reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Magnetar Financial sold 3,811 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.99M.
  • Magnetar Financial first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Magnetar Financial's Madrigal Pharmaceuticals position peaked at $2.04M in Q2 2025.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Magnetar Financial's 13F filing for Q2 2026, filed 14 Aug 2026.